MILATUZUMAB
Milatuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against HLA class II histocompatibility antigen gamma chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 3 | — | — | — | 5 |
| Leukemia | D007938 | — | C95 | 3 | 2 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 2 | — | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 2 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 2 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | 1 | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 1 | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Discoid lupus erythematosus | D008179 | — | L93.0 | 1 | — | — | — | — | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | 1 | — | — | — | — | 1 |
| Central nervous system lupus vasculitis | D020945 | EFO_1001363 | — | 1 | — | — | — | — | 1 |
| Vasculitis | D014657 | EFO_0006803 | M31 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MILATUZUMAB |
| INN | milatuzumab |
| Description | Milatuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743040 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 2OP4E0GC6V (ChemIDplus, GSRS) |
Target
Agency Approved
CD74
CD74
Organism
Homo sapiens
Gene name
CD74
Gene synonyms
DHLAG
NCBI Gene ID
Protein name
HLA class II histocompatibility antigen gamma chain
Protein synonyms
CD74, CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated), CD74 molecule, major histocompatibility complex, class II invariant chain, class II MHC-associated invariant chain peptide, gamma chain of class II antigens, HLA-DR antigens-associated invariant chain, HLA-DR-gamma, Ia antigen-associated invariant chain, Ia-associated invariant chain, Ii, MHC HLA-DR gamma chain
Uniprot ID
Mouse ortholog
Cd74 (16149)
H-2 class II histocompatibility antigen gamma chain (P04441)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 379 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use